List view / Grid view
When the pandemic broke out in 2020, pharmaceutical supply chains showed signs of potential failure across the continent. Now, with COVID-19 cases rising once more, and an end to the problem not yet in sight, we discuss with Medicines for Europe how these supply chains are faring, almost two years…
We are experiencing a time of polarity in our healthcare systems with breakthrough treatment options developed, but access prohibited. Here, Catherine Owen, SVP of Major Markets at Bristol Myers Squibb, explains why, despite continued COVID-19 pressures, the time is ripe to rectify this situation.
Healthcare groups including the US Pharmacopeia and American Medical Association release advice for policymakers on addressing challenges in the US supply chain.
Articles in this in-depth focus explore how to promote patient access to breakthrough treatments across Europe and discuss some of the latest and greatest innovations in packaging.
With global supply chains under stress due the pandemic, European pharma companies are increasingly looking for alternative supply channels.
AstraZeneca has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals for eplontersen.
The license agreement between Pfizer and the Medicines Patent Pool (MPP) will enable access to Pfizer's antiviral candidate in 95 countries.
The European Medicines Agency has endorsed ICMRA recommendations to facilitate the use of track and trace systems for medicinal products at a global level.
In this interview, Adrian van den Hoven, Director General of Medicines for Europe, discusses all things supply of generic and biosimilar medicines for the continent. Also, in a bonus video, Adrian discusses challenges disrupting access to biosimilars and generics in Europe.
Global leaders at the G7 summit pledged 870 million COVID-19 vaccine doses, with half to be delivered by the end of 2021, to COVAX for distribution among low- and middle-income countries.
Here EPR summarises the latest news from Moderna on the licensure, supply and distribution of its mRNA COVID-19 vaccine.
Pfizer and BioNTech have agreed to supply Europe with 900 million additional doses of Comirnaty® with the option to request 900 million more in future.
Learn about current and future European pharmaceutical supply chains from Richard Daniell at Teva Pharmaceuticals in European Pharmaceutical Review’s first podcast.
The dedication of the science community and healthcare workers in the fight against COVID-19 has been unwavering and justly praised. Yet logistics workers and the industries that support it have also achieved tremendous feats to support the resulting aid. Here, Zoe McLernon, Multimodal Policy Manager at Logistics UK, highlights the…
Information is king – and real-time data regarding material stock movements is essential for effective inventory management. Here, Mostafa Eissa from Cairo University demonstrates the use of statistical processing control techniques for monitoring material mobility and how this could benefit the pharma industry.
